ver recent months organisms producing extended-spectrum beta lactamases (ESBLs) have become an increasing problem in hospitals and the community. The situation was mentioned in this year's chief medical officer's report and subsequently received attention from national and local media. The aim of this article is to give an overview of the microbiology of ESBLs, to examine the epidemiology and to look at possible methods of treatment and control.
Alobwede I., M'Zali FH, Livermore DM, Heritage J., Todd N., Hawkey PM (2003) CTX-M extended-spectrum β-lactamase arrives in the UK. J Antimicrob Chemother51(2): 470-1.
2.
Bauernfeind A., Grimm H., Schweighart S. (1990) A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection18(5): 294-8.
3.
Bernard H., Tancrede C., livrelli V., Morand A., Barthelemy M., Labia R. (1992) A novel plasmid-mediated extended-spectrum β-lactamase not derived from TEM- or SHV-type enzymes. J Antimicrob Chemother29(5): 590-2.
4.
Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterisation, epidemiology and detection of this important resistance threat. Clin Microbiol Rev14: 1933-51.
5.
Harvey G. (2004) ESBL-producing E.coli epidemiology: a local overview. PowerPoint presentation. See: www.bsac.org.uk/resource_library (accessed 1 October 2005).
6.
Karas JA, Pillay DG, Muckart D., Sturm AW (1996) Treatment failure due to extended-spectrum β-lactamase . J Antimicrob Chemother37(1): 203-4.
7.
Livermore D., Woodford N. (2004) Guidance to diagnostic laboratories: laboratory detection and reporting of bacteria with extended-spectrum β-lactamases . See: www.hpa.org.uk/srmd/div_nsi_armrl/ESBL_advice_advice_June_2004.pdf (accessed 1 October 2005).
8.
Navarro F., Miró E. ( 2002) Update on CTX-M-type β-lactamases. Rev Med Microbiol13: 63-73.
9.
Paterson DL, Singh N., Rihs JD, Squier S., Rihs BL, Muder R. (2001) Control of an outbreak of infection due to extended-spectrum βlactamase producing Escherichia coli in a liver transplantation unit. CID33(1):126-8.
10.
Public Health Laboratory Service. (2003) First outbreak of infections caused by Klebsiella pneumoniae producing a CTX-M extended-spectrum β-lactamase in the United Kingdom. Commun Dis Rep CDR Wkly (serial online) 13(1): News. See: www.hpa.org.uk/cdr/archives/2003/cdr0103.pdf (accessed 1 October 2005).
11.
Rodriguez-Bano J., Navarro M., Romero L., Martínez-Martínez L., Muniain MA, Perea EJ, Pérez-Cano R., Pascual A. (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in non-hospitalised patients. J Clin Microbiology42(3):1089-94.
12.
Teale C., Barker L., Foster A., Liebana E., Batchelor M., Livermore DM, Threlfall EJ (2005) Extended-spectrum beta-lactamase detected from E. coli recovered from calves in Wales. Vet Rec156(6): 186-7.
13.
Wiener J., Quinn JP, Bradford PA, Goering RV, Nathan C., Bush K., Weinstein RA (1999) Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA281(6): 517-23.
14.
Woodford N., Ward M., Kaufmann M., Turton J., Fagan EJ, James O. (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother54: 735-43.
